H
Henry H. Woo
Researcher at Sydney Adventist Hospital
Publications - 211
Citations - 6106
Henry H. Woo is an academic researcher from Sydney Adventist Hospital. The author has contributed to research in topics: Prostate cancer & Lower urinary tract symptoms. The author has an hindex of 39, co-authored 191 publications receiving 4889 citations. Previous affiliations of Henry H. Woo include Westmead Hospital & Royal Melbourne Hospital.
Papers
More filters
Journal ArticleDOI
A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update
Jean Nicolas Cornu,Sascha Ahyai,Alexander Bachmann,Jean J.M.C.H. de la Rosette,Peter J. Gilling,Christian Gratzke,Kevin T. McVary,Giacomo Novara,Henry H. Woo,Stephan Madersbacher +9 more
TL;DR: A meta-analysis of available randomized controlled trials shows that HoLEP is associated with more favorable outcomes than M-TURP in published RCTs and needs to be refined to propose tailored surgical treatment for benign prostatic obstruction relief.
Journal ArticleDOI
Current Status of Biomarkers for Prostate Cancer
TL;DR: Current efforts to identify biomarkers obtained by minimally invasive methods are highlighted and current knowledge with regard to gene fusions, mRNA and microRNAs, immunology, and cancer-associated microparticles are discussed.
Journal ArticleDOI
Management of stage T1 tumors of the bladder: International Consensus Panel.
Alan M. Nieder,Maurizio Brausi,Donald L. Lamm,Michael A. O’Donnell,K. Tomita,Henry H. Woo,Michael A.S. Jewett +6 more
TL;DR: The International Consensus Panel on T1 bladder tumors markers reviewed the subject from a clinical perspective and made recommendations with supporting evidence.
Journal ArticleDOI
Benign prostatic hyperplasia
Bilal Chughtai,James C. Forde,Dominique Dana Marie Thomas,Leanna Laor,Tania Hossack,Henry H. Woo,Alexis E. Te,Steven Kaplan +7 more
TL;DR: Treatment options for men with BPH start at watchful waiting and progress through medical to surgical interventions, dictated by the starting point on the treatment pathway will be dictated by their symptoms and degree of bother.
Journal ArticleDOI
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Andrew Kneebone,Andrew Kneebone,Carol Fraser-Browne,Gillian M. Duchesne,Gillian M. Duchesne,Richard Fisher,Mark Frydenberg,Alan Herschtal,Scott Williams,Scott Williams,Chris Brown,Warick Delprado,Warick Delprado,Annette Haworth,David Joseph,Jarad Martin,Jarad Martin,John H L Matthews,Jeremy Millar,Mark Sidhom,Mark Sidhom,Nigel Spry,Nigel Spry,Colin Tang,Colin Tang,Sandra Turner,K. Wiltshire,Henry H. Woo,Henry H. Woo,Ian D. Davis,Tee S Lim,Maria Pearse +31 more
TL;DR: Data support the use of salvage radiotherapy as it results in similar biochemical control to adjuvant radiotherapy, spares around half of men from pelvic radiation, and is associated with significantly lower genitourinary toxicity.